Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025 - 2026)
Universe Pharmaceuticals (UPC) posted Current Deferred Revenue of $42012.0 for Q1 2026, up 3.2% sequentially from $40708.0 in Q3 2025.
Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Universe Pharmaceuticals has reported Current Deferred Revenue for 2 years, with the latest figure at $42012.0 in Q1 2026.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $42012.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42012.0 (changed N/A YoY) and the FY2025 annual result came in at $40708.0, changed N/A from the prior year.
- Current Deferred Revenue improved to $42012.0 in Q1 2026 per UPC's latest filing, from $40708.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $42012.0 in Q1 2026 and troughed at $40708.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Universe Pharmaceuticals | 2.93 Mn | -26.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,012.00 |
| Sep 30, 2025 | 40,708.00 |